Table 3.
Hepatic BAs profiles of mice in Experiment 2.
| Variable (nmol/g) | LPSa | GSP + LPS | Gly + GSP + LPS | p -value |
|---|---|---|---|---|
| Total bile acid | 2, 988, 180 | 2, 736, 187 | 3, 259, 204 | 0.19 |
| Unconjugated bile acid | 104, 8.30 | 119, 15.0 | 134, 9.49 | 0.19 |
| Conjugated bile acid | 2, 885, 180 | 2, 617, 182 | 3, 125, 200 | 0.19 |
| Cholic acid | 7.03, 1.14 | 6.54, 1.06 | 7.59, 0.87 | 0.77 |
| Chenodeoxycholic acid | 0.22, 0.05b | 0.68, 0.05a | 0.35, 0.08b | <0.01 |
| ω-muricholic acid | 15.9, 0.56 | 18.2, 2.21 | 20.1, 2.57 | 0.35 |
| α-muricholic acid | 12.6, 1.67 | 14.9, 1.93 | 15.8, 1.66 | 0.48 |
| β-muricholic acid | 49.6, 8.99 | 60.0, 10.7 | 71.7, 10.9 | 0.34 |
| Deoxycholic acid | 0.16, 0.04 | 0.18, 0.04 | 0.20, 0.04 | 0.81 |
| Lithocholic acid | 0.02, 0.00b | 0.09, 0.01a | 0.04, 0.00b | <0.01 |
| Ursodeoxycholic acid | 0.58, 0.12 | 0.71, 0.12 | 0.62, 0.08 | 0.70 |
| Taurocholic acid | 415, 66.9 | 357, 46.2 | 519, 50.1 | 0.14 |
| Taurochenodeoxycholic acid | 40.5, 4.62b | 69.5, 7.05a | 55.4, 7.22ab | 0.02 |
| Tauro-ω-muricholic acid | 205, 21.2 | 186, 28.5 | 210, 29.9 | 0.70 |
| Tauro-α-muricholic acid | 160, 17.7 | 173, 24.1 | 189, 20.1 | 0.62 |
| Tauro-β-muricholic acid | 1, 667, 193 | 1, 463, 162 | 1, 803, 209 | 0.46 |
| Taurodeoxycholic acid | 104, 10.0 | 114, 11.4 | 109, 15.6 | 0.87 |
| Taurolithocholic acid | 5.68, 0.94b | 10.9, 1.09a | 6.37, 1.10b | <0.01 |
| Tauroursodeoxycholic acid | 66.1, 7.54 | 57.4, 9.14 | 72.2, 10.6 | 0.53 |
a, b
In each row, means with the same letter represented no significant differences.
aLPS, a LPS injection group that oral gavaged with physiological saline before i.p. LPS injection. GSP + LPS, a GSP administration group that oral gavaged with 250 mg/kg GSP before i.p. LPS injection; Gly + GSP + LPS, the GSP+LPS group coupled with a dose of 10 mg/kg BW glycine-β-muricholic acid before i.p. LPS injection. n = 6.
BA, bile acid.